Galvus and Galvus Met, new registered medicinal agents for the treatment of diabetes mellitus

diabetes mellitus, new drugs, Galvus, Galvus Met

1. Langley AK., Suffoletta TJ et al. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007; 27:1163-80.

2. Fonseca V, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007; 50: 1148-1155.

3. A. J. Garber, R.-P. Camisasca et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM). Diabetes Obes Metab 10: 1047-1056.

4. Schweizer A, Couturier A., Foley JE et al. Comparison between vildagliptin and metformin to sustain reduction in HbA1c over 1 year in drug-naive patients with Type 2 Diabetes. Diabet Med. 2007; 24: 955-961.

5. Rosenstock J, Baron MA., Dejager S et al. Comparison of vildagliptin and rosiglitazone Monotherapy in patients with Type 2 Diabetes: a 24-week, double-blinde, randomized trial. Diabetes Care 2007, 30: 217-23.

6. Bosi E, Camisasca RP et al.. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-895 .

7. R. Marfella, M. Barbieri et al. Effects of vildagliptin twice daily versus sitagliptin once daily on 24-hour acute glucose fluctuations. Journal Diabetes and its Complications, 2009, in press.